Rhythm Pharmaceuticals Inc., Deciphera Pharmaceuticals LLC, NuCana PLC and Adial Pharmaceuticals Inc. all registered their intent to launch initial public offerings in September, potentially restarting this year's unexpectedly active biopharmaceutical IPO market, which has outperformed so far in 2017.
The third quarter got into a one-per-week pace of first-time offerings by drug developers in the US, but that ended with the industry's 24th IPO this year – an offering...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?